Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes

Haematologica

Volumn 82, Issue 6, 1997, Pages 660-663

  Invernizzi, Rosangela ^a,b   Pecci, Alessandro ^a   Rossi, Giuseppe ^c   Pelizzari, Anna Maria ^c   Giusto, Marcello ^a   Tinelli, Carmine ^b   Ascari, Edoardo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Sezione Ematologia   (Italy)

Author keywords

Acute myeloid leukemia; Chemotherapy; Cytosine arabinoside; Idarubicin

Indexed keywords

CYTARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MYELODYSPLASTIC SYNDROME; THROMBOCYTE TRANSFUSION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; HUMANS; IDARUBICIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RISK FACTORS;

EID: 0031454702     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gallagher A, Darley RL, Padua R. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82:191-204.
2. Aglietta M, De Vincentiis A, Lanaca L, et al. Peripheral blood stem cells in acute myeloid leukemia: biology and clinical applications. Haematologica 1996; 81:77-92.
3. Cheson BD. Chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Oncol 1992; 19:85-94.
4. Gassmann W, Schmitz N, Loeffler H, De Witte T. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Hematol 1996; 33:196-205.
5. Ganser A, Heil G, Kolbe K, et al. Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia. Ann Hematol 1993; 66:123-5.
6. Hoffmann K, Flasshove M, Fricke HJ, et al. Therapy of advanced myelodysplastic syndrome (MDS) with cytarabine and idarubicin (AIDA). Proc Am Soc Clin Oncol 1995; 14:335.
7. Estey EH, Kantarjian H, Keating M. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Semin Oncol 1993; 20(suppl 8):1-5.
8. De Witte T, Suciu S, Peetermans M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9:1805-11.
9. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica 1995; 80:82-90.
10. Mertelsmann R, Thaler HT, To L, et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 1980; 56:773-81.
11. Armitage O, Dick FR, Needleman SW, et al. Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 1981; 65:601-5.
12. Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute non-lymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4:325-45.
13. Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 1986; 63:477-83.
14. Fenaux P, Morel P, Rose C, et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77:497-501.
15. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic features. J Clin Oncol 1986; 4:1748-57.
16. Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 1994; 8:998-1004.
17. Estey E, Pierce S, Kantarjian H, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 1993; 11 (suppl 2):59-63.
18. Economopoulos T, Papageorgiou E, Stathakis N, et al. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Leuk Res 1996; 20:385-90.
19. Ruutu T, Hänninen A, Järventie G, et al. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 1997; 21:133-8.
20. Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Severi F. Myelodysplastic syndromes: the pediatric point of view. Haematologica 1995; 80:268-79.
21. Lambertenghi Deliliers G, Annaloro C, Della Volpe A, et al. Single-institution results of autologous bone marrow transplantation in acute myeloid leukemia. Haematologica 1995; 80:136-41.